Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IBRX
DateTimeSourceHeadlineSymbolCompany
06/13/20245:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
06/13/20245:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
06/13/20245:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
06/13/20245:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
06/13/20245:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
06/13/20245:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
06/12/20243:36PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
06/07/20248:13AMBusiness WireImmunityBio Announces 2024 Annual Meeting of Stockholders with Company UpdateNASDAQ:IBRXImmunityBio Inc
05/17/20248:00AMBusiness WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastNASDAQ:IBRXImmunityBio Inc
05/09/20244:00PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
05/07/20247:00AMBusiness WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®NASDAQ:IBRXImmunityBio Inc
05/02/20243:04PMBusiness WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesNASDAQ:IBRXImmunityBio Inc
04/30/20247:00AMBusiness WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationNASDAQ:IBRXImmunityBio Inc
04/24/202411:03PMBusiness WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerNASDAQ:IBRXImmunityBio Inc
04/22/20248:56PMBusiness WireImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:IBRXImmunityBio Inc
03/06/20248:00AMBusiness WireNIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral TherapyNASDAQ:IBRXImmunityBio Inc
03/05/20248:00AMBusiness WireN-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure StudyNASDAQ:IBRXImmunityBio Inc
02/26/20243:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/26/20243:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/26/20243:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/23/20248:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
02/21/20248:00AMBusiness WireImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the TrialNASDAQ:IBRXImmunityBio Inc
02/06/20248:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/05/20248:00AMBusiness WireImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCGNASDAQ:IBRXImmunityBio Inc
02/02/20246:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/02/20246:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
01/03/20248:59PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:IBRXImmunityBio Inc
01/03/20248:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
01/03/20248:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
01/02/20245:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
 Showing the most relevant articles for your search:NASDAQ:IBRX